Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.

Opsahl JA, Vaudel M, Guldbrandsen A, Aasebø E, Van Pesch V, Franciotta D, Myhr KM, Barsnes H, Berle M, Torkildsen Ø, Kroksveen AC, Berven FS.

Proteomics. 2016 Apr;16(7):1154-65. doi: 10.1002/pmic.201500284.

PMID:
26841090
2.

Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.

Bastos P, Ferreira R, Manadas B, Moreira PI, Vitorino R.

Crit Rev Clin Lab Sci. 2017 May;54(3):185-204. doi: 10.1080/10408363.2017.1299682. Epub 2017 Apr 10. Review.

PMID:
28393582
3.

Antibody-based profiling of cerebrospinal fluid within multiple sclerosis.

Häggmark A, Byström S, Ayoglu B, Qundos U, Uhlén M, Khademi M, Olsson T, Schwenk JM, Nilsson P.

Proteomics. 2013 Aug;13(15):2256-67. doi: 10.1002/pmic.201200580. Epub 2013 Jun 25.

PMID:
23696371
4.

Characterization of individual mouse cerebrospinal fluid proteomes.

Smith JS, Angel TE, Chavkin C, Orton DJ, Moore RJ, Smith RD.

Proteomics. 2014 May;14(9):1102-6. doi: 10.1002/pmic.201300241. Epub 2014 Mar 20.

5.

Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.

Chiasserini D, van Weering JR, Piersma SR, Pham TV, Malekzadeh A, Teunissen CE, de Wit H, Jiménez CR.

J Proteomics. 2014 Jun 25;106:191-204. doi: 10.1016/j.jprot.2014.04.028. Epub 2014 Apr 24.

PMID:
24769233
6.
7.

Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis.

Rosenling T, Stoop MP, Attali A, van Aken H, Suidgeest E, Christin C, Stingl C, Suits F, Horvatovich P, Hintzen RQ, Tuinstra T, Bischoff R, Luider TM.

J Proteome Res. 2012 Apr 6;11(4):2048-60. doi: 10.1021/pr201244t. Epub 2012 Feb 23.

PMID:
22320401
8.

Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.

Kroksveen AC, Guldbrandsen A, Vedeler C, Myhr KM, Opsahl JA, Berven FS.

Acta Neurol Scand Suppl. 2012;(195):90-6. doi: 10.1111/ane.12029.

PMID:
23278663
9.

CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.

Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mogel H, Palm C, Hirt V, Suessmuth SD, Sapunova-Meier I, Ludolph AC, Brettschneider J.

Neurosci Lett. 2009 Mar 13;452(2):214-7. doi: 10.1016/j.neulet.2009.01.057. Epub 2009 Jan 29.

PMID:
19383442
10.

Decreased Neuro-Axonal Proteins in CSF at First Attack of Suspected Multiple Sclerosis.

Stoop MP, Runia TF, Stingl C, van der Vuurst de Vries RM, Luider TM, Hintzen RQ.

Proteomics Clin Appl. 2017 Dec;11(11-12). doi: 10.1002/prca.201700005. Epub 2017 Oct 23.

PMID:
28941200
11.

A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases.

Menon KN, Steer DL, Short M, Petratos S, Smith I, Bernard CC.

Mol Cell Proteomics. 2011 Jun;10(6):M110.000042. doi: 10.1074/mcp.M110.000042. Epub 2011 Mar 18.

12.

Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome.

Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH.

PLoS One. 2011 Feb 23;6(2):e17287. doi: 10.1371/journal.pone.0017287.

13.

A rapid method for preparation of the cerebrospinal fluid proteome.

Larssen E, Brede C, Hjelle AB, Øysaed KB, Tjensvoll AB, Omdal R, Ruoff P.

Proteomics. 2015 Jan;15(1):10-5. doi: 10.1002/pmic.201400096. Epub 2014 Dec 3.

PMID:
25307358
14.

Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.

Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS.

J Proteomics. 2011 Apr 1;74(4):371-88. doi: 10.1016/j.jprot.2010.11.010. Epub 2010 Nov 25. Review.

PMID:
21111852
15.

2D DIGE of the cerebrospinal fluid proteome in neurological diseases.

Tumani H, Lehmensiek V, Lehnert S, Otto M, Brettschneider J.

Expert Rev Proteomics. 2010 Feb;7(1):29-38. doi: 10.1586/epr.09.99. Review.

PMID:
20121474
16.

Preparation of human cerebrospinal fluid for proteomics biomarker analysis.

Waybright TJ.

Methods Mol Biol. 2013;1002:61-70. doi: 10.1007/978-1-62703-360-2_5.

PMID:
23625394
17.

CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis.

Chiasserini D, Di Filippo M, Candeliere A, Susta F, Orvietani PL, Calabresi P, Binaglia L, Sarchielli P.

Eur J Neurol. 2008 Sep;15(9):998-1001. doi: 10.1111/j.1468-1331.2008.02239.x. Epub 2008 Jul 15.

PMID:
18637954
18.

Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM.

Kroksveen AC, Aasebø E, Vethe H, Van Pesch V, Franciotta D, Teunissen CE, Ulvik RJ, Vedeler C, Myhr KM, Barsnes H, Berven FS.

J Proteomics. 2013 Jan 14;78:312-25. doi: 10.1016/j.jprot.2012.09.037. Epub 2012 Oct 8.

PMID:
23059536
19.

Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis.

D'Aguanno S, Barassi A, Lupisella S, d'eril GM, Del Boccio P, Pieragostino D, Pallotti F, Carelli V, Valentino ML, Liguori R, Avoni P, Bernardini S, Gambi D, Urbani A, Federici G.

J Neuroimmunol. 2008 Jan;193(1-2):156-60. Epub 2007 Dec 3.

20.

Between-gel reproducibility of the human cerebrospinal fluid proteome.

Terry DE, Desiderio DM.

Proteomics. 2003 Oct;3(10):1962-79.

PMID:
14625859

Supplemental Content

Support Center